Market Intelligence Reports

Market Intelligence reports article is about information and analysis of a commerical market

[martynnx-blog]

Surgical lighting system Market Key Players, Industry Overview, Supply Chain and Analysis to 2018-2026

Surgical lighting system is an integral component during surgeries to provide illumination that assists the surgeons to view surgical site. There are several types of surgical lights available in the market such as ceiling mounted, mobile surgical lights, surgical headlights, and wall mounted surgical lights. Light source plays an important role in surgical lighting systems for proper illuminations. Manufacturers are engaged in developing efficient surgical light sources. For instance, in February 2016, Excelitas Technologies Corp., a global technology provider focused on delivering innovative, customized photonic solutions, launched its new XLMii LED Fiber Optic Light Source for medical applications. The new XLMii Fiber Optic LED Light Source offers high output and high color rendering index (cri) for endoscopy, surgical microscopy, and surgical headlamps.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2547

The global surgical lighting system market size was valued at US$ 394.1 million in 2017, and is expected to witness a CAGR of 4.4% during the forecast period (2018 – 2026).

Market Dynamics

Increasing number of product innovation and launches of surgical lighting systems are expected to drive growth of the surgical lighting system market. For instance, in March 2017, Orascoptic, a provider of vision solutions for dental and medical professionals, launched Endeavour XL, surgical headlight. Endeavour XL is designed to emit high level of light, and it is consists of Orascoptic’s smallest headlight and longest-running battery pack, providing 24 hours of illumination. Moreover, in July 2018, Hipac Healthcare Ptv. Ltd., introduced brighter surgical headlight, MedLED Chrome with 275,000 Lux. It is customisable to suit the requirements of any surgeon and any procedure, with 3 bezels, MC3, MC6 or MC7 Pro, of varied brightness combined with the 4 MedLED Pillars.

Increasing number of product launches is contributing growth of the surgical lighting system market

New product launches with advanced technology by key players is a major driver for growth of the surgical lighting systems market. For instance, in July 2017, Merivaara, provider of wide range of high-quality equipment and solutions, launched new surgical light, Merivaara Q-Flow to improve working environment in operating theatres and reduce risk of infection. Merivaara Q-Flow offers color rendering, particularly in red and skin shades, that helps the surgeons to perform surgeries such as internal or plastic surgery with precision.

Furthermore, in June 2013, Maquet Medical Systems USA, received U.S. Food and Drug Administration (FDA) 510(k) clearance for Volista Surgical Lighting System. With Volista product range, the company offers product line that combines lighting, suspension, and multimedia equipment in surgical theater. Volista product range is comprised of VOLISTA Access and VOLISTA StandOP.

Increasing demand for surgical equipment with advanced technology by the multispecialty hospitals is expected to show significant growth for the surgical lighting system market. For instance, in May 2014, as per data published by Modern Healthcare/ECRI Institute Technology Price Index, the average prices paid for surgical lights was raised by 30% due to increased number of hospitals that have purchased highly configured and expensive systems.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2547

Surgical Lighting System Market – Competitive Landscape

Key players operating in the surgical lighting system market include STERIS plc., DRE Veterinaryl, Integra LifeSciences, Torontech Inc., Getinge AB, SKYTRON, Meditech, EMA-LED GmbH, NUVO, Trumpf Medical, Symmetry Surgical, S.I.M.E.O.N. Medical GmbH & Co. KG, Amico Group of Companies, MAQUET Holding B.V. & Co. KG, and Drägerwerk AG & Co. KGaA.

[martynnx-blog]

Digestion Aids Market 2018–2026: Analysis, Competitor landscape, Impact of drivers, Trends, drivers, Market challenges, Size

The changing lifestyle and diet is leading to digestive disorders in millions of people worldwide. Increasing awareness regarding gastrointestinal health, fitness, and overall wellbeing is driving the digestive aids market growth. Digestive aids are the supplements used to improve digestion and help in breakdown of consumed food particles. Digestive aids help in treating problems such as constipation, gas, acidity, Gastro-esophageal Reflux Disease (GERD), irritable bowel syndrome, etc. Digestion aids products include prebiotics, probiotics, and digestive enzymes. Enzymes such as lactases, lipases, proteases are marketed as dietary supplements. New lactose free products are gaining significant traction as compared to traditional digestive aids, which can be used for the population suffering from lactose intolerance.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2539

Global Digestion Aids Market: Drivers

Digestion aids market revenue is expected to witness significant growth, owing to increasing number of new product launches for digestive health in children. For instance, in July 2017, Alcresta Therapeutics received 510(K) clearance from the U.S. Food and Drug Administration (FDA) for the use of RELiZORB in children. RELiZORB is used for Pancreatic and Gastric disorders in both children and adults.

Rising geriatric population and growing awareness regarding gastrointestinal health are also two important factors driving the digestion aids market size. In elderly population functionality of digestive system decreases and muscles in the digestive tract become stiff, weak, and less efficient for food digestion. For instance, according to a study published in BMC Gastroenterology Journal, around 11% of the population suffer from a chronic digestive disease in U.S. with a prevalence rate as high as 35% for those 65 years and above.

Global Digestion Aids Market Restraints

The major restraining factor for digestion aids market growth is the side effects shown by the probiotics and prebiotics. Although there are many benefits, but excess consumption of probiotics can lead to unpleasant digestive symptoms. Amines in probiotic foods may trigger headaches, while some ingredients can cause adverse reactions. According to a study published in National Center for Biotechnology Information (NCBI) in 2012, certain probiotic compounds may contain hidden allergens of food and may not be safe for subjects with allergy to cow’s milk or hen’s egg.

Global Digestion Aids Market: Regional Analysis

North America is expected to hold the dominant position in digestion aids market over the forecast period, owing to increasing digestive disorders among the population coupled with unhealthy and sedentary lifestyle. According to the World Gastroenterology Organization (WGO) 2015 data, around 13.8% to 25.8% population in North America is affected by GERD.

Asia Pacific digestion aids market revenue is expected to witness significant growth owing to increasing consumption of probiotics, prebiotics and new launches of digestion aids. For instance, in February 2018, Yakult Danone launched a new version of signature probiotic drink in India. The new formulation contains vitamin D and E, as well as Yakult’s trademark Lactobacillus casei strain Shirota (LcS).

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2539

Global Digestion Aids Market: Competitive Landscape

Key players operating in the global digestion aids market include Nebraska Cultures Inc., Chr. Hansen, Yakult Honsha Co. Ltd., Abbott Laboratories, and Dabur India Ltd. Other prominent players in the digestion aids market are GlaxoSmithKline Plc., Amway Inc., Pfizer, Cargill Inc., and Nestle.

[martynnx-blog]

Microscopic Polyangiitis Market 2018 Competition by Key Players/Suppliers, Business Tactics, Gross Margin by Applications Forecast 2026

Microscopic polyangiitis (MPA) occurs due to inflammation of blood vessels resulting in damage to other organs, mostly kidney, lungs, nerves, skin, and joints. MPA is an immune system mediated disorder, however the exact reason leading to immune system dysfunction is unknown. Since MPA affects multiple organs, various symptoms such as illness, fatigue, fever, loss of weight and appetite, coughing blood in case of lungs, and loss of sensation in case of nerves can be seen. Diagnosis involves blood test for antineutrophil cytoplasmic antibodies (ANCA), urine test for detection of red blood cells (RBCs), and imaging techniques such as computed tomography (CT), magnetic resonance (MR) scan, and X-rays. If results of these tests are positive for presence of MPA, biopsy (tissue sample testing) is performed for confirmation of presence of MPA.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2529

Microscopic Polyangiitis Market Drivers

In the recent past, various regulatory bodies such as European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), Medicines and Healthcare products Regulatory Agency (MHRA), and others have granted treatment related approvals. Such treatment approvals are expected to propel the global microscopic polyangiitis market growth over the forecast period. For instance, in October 2018, Genentech, Inc., a San Francisco-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) to update the Rituxan label to include the follow-up treatment information of adult patients suffering from granulomatosis with polyangiitis and microscopic polyangiitis, who had shown improvement in medical condition with the glucocorticoid and cyclophosphamide induction treatment.

Launch of new treatment methods by key players is expected to drive the global microscopic polyangiitis market growth over the forecast period. For instance, in July 2018, InflaRx N.V., a German clinical stage bio-pharmaceutical company, received an approval from the U.S. Food and Drug Administration (FDA) for conducting phase-2 clinical trials to assess the safety and effectiveness of IFX-1 for treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of which indicates that the patient is suffering from microscopic polyangiitis. IFX-1 is an inhibitor of the complement system (a component of immune system) and neutralizes C5a component without affecting the normal immune functions. These factors are expected to drive the global microscopic polyangiitis market growth over the forecast period.

Microscopic Polyangiitis Market Restraints

The corticosteroids have side effects, which include skin thinning and intense pain. The monoclonal antibody production involves costly and time consuming research. Azathioprine involves side effects such as diarrhea, joint pain, loss of coordination, seizure, and vision changes. These factors are expected to restrain the global microscopic polyangiitis market growth over the forecast period.

Microscopic Polyangiitis Market Regional Analysis

Europe microscopic polyangiitis market is expected to witness significant growth over the forecast period, owing to proposed product launches. For instance, Bristol-Myers Squibb Company is conducting phase lll clinical trials for Abatacept (Orencia), which is expected to be completed by September 2022. Orencia is a recombinant protein, which inhibits the T lymphocyte activation pathway, thereby suppressing the immune system.

In March 2018, Amerigen Pharmaceuticals Limited, a China-based generic pharmaceutical company, was granted approval for its Abbreviated New Drug Application (‘ANDA’), by the U.S. FDA, for its cyclophosphamide capsules 25mg and 50mg. Cyclophosphamide is an immunosuppressive agent used for the treatment of microscopic polyangiitis in combination with corticosteroids. This is expected to propel the Asia Pacific microscopic polyangiitis market growth over the forecast period in turn supporting global microscopic polyangiitis market growth.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2529

Microscopic Polyangiitis Market Key Players

Some of the key players operating in the global microscopic polyangiitis market include Genentech, Inc., Celltrion, Inc., InflaRx N.V., ChemoCentryx Inc., Bristol-Myers Squibb Company, Teijin Pharma Ltd, Amerigen Pharmaceuticals Limited, Sandoz International GmbH (Novartis Division), and TTY Biopharm Company Ltd.

[martynnx-blog]

Orexin Receptors (Hypocretin Receptor) Antagonist Market Report 2026: Competition, Concentration Rate, Production Status and Outlook and Future Predictions

Orexin (hypocretin) is a neuropeptide produced by the lateral hypothalamus which regulates the wakefulness, appetite, arousal and other habits. Orexin receptor antagonist is the new class of drugs are used in the treatment of insomnia.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2522

Suvorexant, is a dual orexin receptor antagonist drug that blocks both pathways of OX1R and OX2R. It develops sleep by the binding inhibition of orexin A and B, neuropeptides that promote wakefulness. Approximately 70,000 orexin neurons are present in the human brain, located in the perifornical lateral hypothalamus, which send signals throughout the brain and spinal cord.

Global Orexin Receptors Antagonist Market Drivers

The main growth driver for the Orexin receptors antagonist market is the rising cases of insomnia. Insomnia is caused by plenty of reasons such as anxiety, stress and depression. Lifestyle problems can trigger insomnia like irregular sleeping patters, drinking alcohol and smoking tobacco products before going to bed. Rising geriatric population, increased stress levels in urban population also results into insomnia. According to American Academy of Sleep Medicine AASM) as reported in 2014  insomnia affects 30% of adults, 15-20% have short term insomnia and 10% of adults have chronic insomnia worldwide.

Growing awareness about insomnia and penetration of Belsomra into the market is expected to create more demand in ORA market.  Moreover, studies are being conducted whether suvorexant can be used to treat depression and anxiety so that the ORA market can witness further growth.

Global Orexin Receptors Antagonist Market Restraints

Though suvorexant (Orexin Receptors Antagonist) is the best drug available against insomnia, other classes of drugs such as Benzodiazepines, Non-benzodiazepines, Antidepressants, Melatonin Antagonist and medical devices like 2Breathe Sleep Inducer, Sleep Shepherd Blue, Dreem Headband, Fisher Wallace Stimulator, SR1 Delta Sleeper can also be used to treat insomnia which can negatively impede the market growth. Moreover, in National Sleep Foundation (NSF) stated that in the year 2010 only 15% of people were diagnosed with insomnia and only 6% receive the treatment for the same. General negligence among the people about insomnia and the side effects of drugs such as headache, sleepiness, next day drowsiness, weight loss restricts the patients from using this medication.

Furthermore, clinical studies by NCBI in 2015 showed the placebo treatment for insomnia is also effective for the patients which hampers the growth of ORA market.

Global Orexin Receptors Antagonist Market Regional analysis

North America is leading the Orexin receptors antagonist market. Rising demand for insomnia treatment in the U.S. and Canada coupled with increase in awareness, and high healthcare spending are anticipated to drive the market. Moreover, high prevalence of insomnia among geriatric population in the U.S. are expected to increase the demand. According to AASM in 2017 30-50% population of U.S. over the age of 60 has developed insomnia.

In Asia Pacific, China is expected to show lucrative growth in the market owing to high prevalence of insomnia. According to China National Knowledge Interne (CNKI) in 2017 15% of China’s population is suffering from insomnia aging 43 and above From the Journal of Community Medicine & Health Education as reported in 2017 in India 72% of population above the age of 60 has insomnia. Asia Pacific is anticipated to witness significant growth in near future because of shift-work disorder and increasing stress level is expected to increase the number of paitents in Asia Pacific. In addition, favorable reimbursement policies for therapeutic products, strong product pipeline, and rising stress level are other reasons contributing to the growth.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2522

Global Orexin Receptors Antagonist Market Key Players

Key competitors in the global Orexin receptors antagonist market include Merck & Co. Inc., Sanofi, Pfizer, Inc., Takeda Pharmaceutical Company Ltd., Purdue Pharmaceuticals L.P., Eisai, Co. Ltd., Meda Consumer Healthcare Inc., Pernix Therapeutics, Vanda Pharmaceuticals, and ECR Pharmaceuticals.

[martynnx-blog]

Aromatherapy Market Prospects & Growth Trends Recorded until 2026

Aromatherapy is a holistic healing treatment that uses natural plant extracts to promote health and well-being. It’s also called as essential oil therapy, as essential oils are major components of aromatherapy. Aromatic essential oils help to improve the health of the body, mind, and spirit. It enhances both physical and emotional health.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2517

Aromatherapy is thought of as both an art and a science. Aromatherapy has numerous benefits some of them include management of pain, improve sleep quality, reduce stress, depression and anxiety, treat headaches and migraines, ease discomforts of labor, fight bacteria, virus or fungus, and boost immunity. Most popular essential oils of aromatherapy are eucalyptus, lavender, lemon, lemongrass, rosemary, geranium, chamomile, and tea tree oil.

Global Aromatherapy Market: Drivers

The aromatherapy market revenue is expected to witness significant growth, owing to its increasing adoption and wide range of application. Aromatherapy along with essential oils are used to combat the side effects of chemotherapy such as nausea, vomiting, anxiety, and depression. For instance, a study published in the journal Oncology Nurse Advisor in May 2018, stated that patients who had undergone brachytherapy – a treatment that delivers a targeted dose of radiation to tumors inside the body – experienced a 60 percent reduction in pain and a 20 percent reduction in anxiety after receiving essential oil aromatherapy and 30 minutes of foot reflexology therapy prior to their treatment sessions.

Furthermore, aromatherapy is widely used in skincare and beauty products, owing to increasing demand for herbal products, which contributes to aromatherapy market growth. For instance, according to studies published in National Center for Biotechnology Information (NCBI) in 2018, acne treatment cream with combination of 20% propolis, 3% tea tree oil, and 10% Aloe Vera reduces acne efficiently in 15-30 days, owing to antibacterial and antifungal effects of tea tree oil.

Global Aromatherapy Market: Restraints

Essential oils are only for topical use and inhalation use, essentials oils can be poisonous if swallowed or used improperly. Essential oils are very concentrated, they are always used in minimum amount and diluted with carrier oil. The aromatherapy market growth is hampered, owing to improper use, which shows side effects such as rashes, asthma attacks, headaches, allergic reactions, skin irritation, and nausea. An experimental study was conducted in Taipei Medical University in 2012, where 100 healthy people were exposed to a room, which contained tiny droplets of essential oil of bergamot infused in air for 2 hours. After 75 minutes, the condition of people began to deteriorate, the blood pressure, heart rate dropped and people started to feel sick.

According to International Fragrance Association (IFRA) 2017 report, some oils should be completely avoided due to their toxicity. IFRA has banned many essential oils such as almond (bitter), aniseed, boldo, calamus, camphor, cassia, horseradish, mugwort, mustard, pennyroyal, rue, sassafras, savin, tansy, thuja, wintergreen, and wormwood till date.

Global Aromatherapy Market: Regional Analysis

North America is expected to hold the dominant position in the aromatherapy market over the forecast period, owing to presence of major companies in the U.S., which include doTERRA International, Young Living Essential Oils, Frontier Natural Products Corporation, Rocky Mountain Oils, Mountain Rose Herbs, Edens Garden, and Plant Therapy.

Asia Pacific is anticipated to witness significant growth due to increasing demand for use of essential oils for treating burns, scars, and related infections. According to Asian Pacific Journal of Tropical Biomedicine 2015 reports, Eucalyptus and Lavender essential oils are widely used for soothing burns and helping prevent burns from becoming infected, owing to anti-microbial and anti-inflammatory property of the oils. It is also used to treat other skin problems such as cuts, lice, and insect bites.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2517

Global Aromatherapy Market: Competitive Landscape

Key players operating in the global aromatherapy market include doTERRA International, Eden Garden, Young Living Essential Oils, Frontier Natural Products Corporation, Rocky Mountain Oils, Mountain Rose Herbs, Plant Therapy Inc., Thann-Oryza Co. Ltd., G Baldwin & Co., Ouwave Aroma Tech Co., Ltd., RyohinKeikaku Co. Ltd. (Muji), and Zija International, and Plant Therapy Essential Oils.

[martynnx-blog]

Blood Dialyzer Market: Demand for Health Supplement to Boost Growth By 2026

The process of hemodialysis remains the popular renal replacement therapy in most countries, worldwide. During the last decade, there has been an increasing interest in understanding the needs of hemodialysis patients. Various risk factors, such as failures, adverse reactions, and poor outcomes of older dialysis methods are setting path for higher demand for blood dialyzers, thus propelling the overall market growth.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2503

Blood dialyzers, also called hemodialyzer, are mainly used for the removal of excess fluid accumulated in kidney. Excess fluid is removed by creating a pressure gradient across two compartments of dialyzer. Three primary methods commonly used to gain access to the blood during hemodialysis are: intravenous catheter, arteriovenous fistula (AV), and synthetic graft. The type of access to these methods is determined by factors such as the expected time course of a patient’s renal failure and the condition of vasculature of patient.

The global blood dialyzer market size was valued at US$ 4,682.7 million in 2017, and is expected to witness a CAGR of 6.1% during the forecast period (2018 – 2026).

Rising Global Burden of Kidney Diseases is expected to Drive Growth of the Blood Dialyzer Market

Global burden of kidney diseases, which have direct impact on global morbidity and mortality rate is continuously rising and in turn fuels growth of the blood analyzer market. For instance, the Global Burden of Disease (GBD) 2015 study, estimated that 1.2 million people died from kidney failure in 2005-2015, an increase of 32% since 2005. Additionally, overall, an estimated 5–10 million people die annually, from kidney disease.

Furthermore, kidney disease is associated with a tremendous economic burden. GBD 2015 study states, high-income countries typically spend over 2–3% of the annual health-care budget on the treatment of end-stage kidney diseases, which is expected to favor the blood dialyzer market.

Market Dynamics

Prevalence of kidney diseases is increasing globally, due to rising geriatric population, urinary disorders, and changing lifestyles. According to United Nations, Department of Economic and Social Affairs, Population Division, the global population aged 60 and above increased by 68% in urban areas and by 25% in the rural areas, between 2000 and 2015. Rising geriatric population will increase the chances for kidney diseases, which will be influencing favorably for sustained growth of the blood dialyzer market over the next decade.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2503

Blood Dialyzer Market- Competitive Landscape

Key players operating in the blood dialyzer market include Baxter International, Inc., Nikkiso Co. Ltd., B. Braun Medical Inc., Nipro Corporation, CVS Health., Diaverum Deutschland GmbH, NxStage Medical, Inc., Fresenius Medical Care AG & Co. KGaA, and DaVita Healthcare Partners, Inc.

[martynnx-blog]

Proteomics  Market to Represent a Significant Expansion of CAGR During 2018–2026

Proteomics is a study of large scale proteomes. Proteomes are entire complements of protein expressed by a tissue, cell or organism. Proteomics aims to interpret the roles of large number of proteins made from combining 22 genetically-encoded amino acids. It helps to understand the structure, function, and interactions of the entire protein content in a specific organism. It is used to investigate protein expression, rates of protein production, degradation, modification of protein, protein movements in subcellular compartments, and protein-protein interaction.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2493

Global Proteomics Market: Drivers

Key players in the market are focused on introducing new and improved proteomics techniques, which is expected to boost the proteomics market growth. For instance, in September 2017, Bruker Corporation launched timsTOF Pro system for parallel accumulation and serial fragmentation (PASEF) mass spectrometry— using proprietary trapped ion mobility spectrometry (TIMS) technology—to offer efficient data acquisition speed for shotgun proteomics.

Moreover, in October 2018, Bruker Corporation introduced a next-generation workflow for the timsTOF Pro mass spectrometer at Human Proteome Organization (HUPO). The platform for timsTOF Pro workflow includes large-scale, reproducible, and accurate collision cross section (ccs) values for tryptic peptides, fastpro, and ccs-based lipidomics workflow.

Moreover, in 2017, Diagenode, a provider of complete solutions for epigenetics research and sample preparation, in collaboration with PreOmics GmbH, developer and provider of innovative tools for MS-based proteomics, launched new streamlined sample preparation solution for proteomic analyses. The new solution was developed by combining PreOmics in-StageTip Kit (iST Kit) and the Diagenode Bioruptor sonication system to clean peptides for mass spectrometry (MS) analysis.

Global Proteomics Market: Regional Analysis

On the basis of region, the global proteomics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to account for the largest market share in the proteomics market over the forecast period. The market growth is attributed to increasing collaboration and partnership activities by key players in this region. For instance, in November 2018, Thermo Fisher Scientific Inc. and Symphogen entered into a two-year collaborative partnership to deliver validated platform workflows for simplified characterization and quality monitoring of complex therapeutic proteins. Under this agreement, Symphogen would have access to Thermo Fisher’s Q Exactive Plus Orbitrap liquid chromatography-tandem mass spectrometry (LC-MS/MS) system with BioPharma Option for creating, testing, and validating the platform workflows for intact and native mass analysis of therapeutic monoclonal antibody (mAb) mixtures. Moreover, Symphogen will focus on the development of automated multi-attribute method (MAM) workflows for monitoring critical quality attributes of proteins using high-resolution accurate-mass mass spectrometry in a quality control environment.

Increasing government initiatives to promote research and development in proteomics, genomics, and bioinformatics is expected to propel Asia Pacific proteomics market growth during the forecast period. For instance, the 13th International Conference on Proteomics, Genomics, and Bioinformatics will be held on May 10-11, 2019 in Tokyo, Japan. The theme of the conference will be ‘Leading Edge Innovations in Life Sciences’ and the objective will be to explore the recent advancements and new methodologies that can be applied to the research to make proteomics and bioinformatics more advance. Target audience for the upcoming conference can be health professionals, researchers and scientists, management/business leaders and/or agents, government/non-government community groups or individuals, professors, psychiatrist, and therapists.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2493

Key players operating in the global proteomics market include, Thermo Fisher Scientific Corporation, Agilent Technologies, Luminex Corporation, Danaher Corporation, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Waters Corporation, Caprion Proteomics Inc., PerkinElmer, Inc., Biognosys Inc., Bruker, Cell Signaling Technology, Inc., Newomics, Inc., Proteome Sciences, Applied Biomics, Inc., Courtagen Life Sciences, Inc., Xcelris Genomics., Center for Genomic Sciences, and Sera Prognostics, Inc.

[martynnx-blog]

Technical Breakthrough And A Competitive Outlook To Stay Abreast On The Key Trends Impacting This Animal Model  Market By 2026

Most of the biomedical researches are carried on animal model with short-term objective to study toxicity of drugs for developing new therapeutics for certain diseases. The main objective of using animal model in research is to determine how the animal will respond to the treatment. The anatomical and physiological similarities between humans and animals help the researchers to investigate novel therapies in animal models before applying it on humans. The use of animal model in research is based on fact that human diseases can affect other animal species. It is not only limited for infectious diseases but also for common diseased conditions including diabetes, hypertension, cancer, epilepsy, and others.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2488

Animal Model Market Outlook

Increasing number of research based on animal test to develop novel drugs is a major factor that boosts the animal model market growth. For instance, as per data reported in Annual Statistics of Scientific Procedures on Living Animals, about 3.79 million scientific procedures were carried out on protected living animals in Great Britain in 2017. Moreover, as per data in Worldwide Animal Research Statistics, in 2016, 3,789,373 vertebrates per procedure and 110,553 mammals per procedure (excluding rats and mice) have been used in research experiments conducted in the U.S.

However, rising concern for animal welfare by social and government organizations leads to use lesser number of animals in research purpose, which may hamper growth of the animal model market.

Animal Model Market Regional Analysis

On the basis of region, the global animal model market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Geographically, North America is expected to witness conducive growth for animal model market, owing to high presence of major market players in this region. For instance, in September 2018, Taconic Biosciences, a U.S. based company providing genetically engineered rodent model solutions, announced partnership plans with Government Scientific Source (GSS) to become the first animal model provider on general services administration contract schedule. Taconic Bioscience’s products are fit into GSS effort to support biomedical research solutions within the U.S. federal government.

Moreover, in November 2018, Jackson Laboratory, an independent, nonprofit biomedical research institution headquartered in Maine, the U.S., established a dedicated quarantine facility for the importation of JAX Mice into China. Thus, expansion of facilities by manufacturers in Asia Pacific is expected to show high growth of the market during the forecast period.

Increasing use of animal models in research for developing vaccines is another major factor, which will show significant growth for animal model market in Europe. For instance, in November 2018, in the workshop organized by EDUFLUVAC consortium, a European Union funded project, coordinated by the European Vaccine Initiative, experts from influenza vaccine community gathered to discuss the current knowledge and future perspectives for testing broadly reactive influenza vaccines in animal models. The workshop has been organized for summarizing the outcome of “Experimental animal models for universal influenza vaccines” project.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2488

Key players in the animal model market include Charles River Laboratories International, Inc., Horizon Discovery Group plc, The Jackson Laboratory, Trans Genic Inc, Taconic Biosciences, Inc., Genoway SA, Eurofins Scientific SE, Crown Bioscience, Inc., Harbour Antibodies BV, Envigo CRS SA, Ingenious Targeting Laboratory, and Transposagen Biopharmaceuticals, Inc.

[martynnx-blog]

Adult and Pediatric Hemoconcentrators Market Report 2018: Competition, Concentration Rate, Production Status and Outlook and Future Predictions

A hemoconcentrator is a device used for removal of fluid during cardio bypass surgery. Hemoconcentrators are introduced in extracorpeal circuit where it controls hemodilution, maintains hematocrit levels, and reduces the need for additional blood products during and after surgery. Hemoconcentrators are widely used during cardiac bypass surgery and has become the ideal method for controlling hemodilution during cardiopulmonary surgery by surgeons and perfusionists.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2483

High prevalence of cardiovascular diseases is expected to lead to high demand for hemoconcentrators and thus drive the adult and pediatric hemoconcentrators market growth

Hemoconcentrators are widely used devices during cardio bypass surgery. High prevalence of cardiovascular diseases is expected to be a major factor propelling demand for hemoconcentrator. According to the data published by World Health Organization (WHO) in 2017, cardiovascular diseases is the leading cause of death globally. Annually, more people die from cardiovascular diseases than from any other cause.

According to the data published by World Health Organization (WHO) in 2018, an estimated around 17.7 million people died from cardiovascular diseases in 2015, representing 31% of all global deaths. Such high prevalence of cardiovascular diseases is expected to lead to high demand for hemoconcentrators and drive global adult and pediatric hemoconcentrators market growth over the forecast period.

Key players in the market include Terumo Corporation, LivaNova Plc., Medtronic Plc., etc. All these key players manufacture and market their own novel hemoconcentrators developed from different materials with different advantages. For instance, in 2011 Minntech Corporation (a Cantel Medical Corporation company) introduced The Hemocor HPH Hemoconcentrator made with Eastman Chemical Company’s Tritan Copolyester. Tritan is a new-generation copolyester that offers the benefits of toughness, chemical resistance, and color stability after sterilization for renal medical device housings.

The global adult and pediatric hemoconcentrators market size was valued at US$ 10.7 Mn in 2017, and is expected to witness a CAGR of 3.3% during the forecast period (2018 – 2026).

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2483

North America is expected to hold dominant position in the market, owing to frequent approvals of new adult and pediatric hemoconcentrators by regulatory bodies

North America is expected to hold dominant position in global adult and pediatric hemoconcentrators market over the forecast period, owing to high prevalence of cardiovascular diseases in the U.S. and rising healthcare awareness in region.

Key players operating in the global adult and pediatric hemoconcentrators market include Medivators Inc., Terumo Corporation, LivaNova, PLC, Maquet (a Getinge Group company), Medica S.p.A, and others.

[martynnx-blog]

Influx of Technologically Advanced Bioresorbable Vascular Scaffold Drives the Bioresorbable Vascular Scaffold Market – 2026

Bioresorbable vascular stents expand the blood vessel to prevent a blockage, which are disintegrated in human body without any external intervention. It prevents inflammation leading to stent restenosis and thrombosis and eliminates the need for post-treatment involvements. Bioresorbable stents are superior over 1st and 2nd generation stents as Bioresorbable stents cut the need for dual antiplatelet therapies.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2471

The global bioresorbable vascular scaffold market size was valued at US$ 147.0 million in 2017, and is expected to exhibit a CAGR of 12.5% over the forecast period (2018 – 2026).

Market Dynamics

Increasing demand for bioresorbable vascular scaffold owing to high prevalence of coronary heart disease, ischemic heart disease, and other cardiovascular diseases is expected to drive market growth. According to American Heart Association Council, in 2015, cardiovascular disease was the leading cause of death in the world, accounting for over 17.9 million deaths per year globally, and this number is expected to increase to over 23.6 million by 2030. From the same source, cardiovascular diseases accounted for nearly 836,546 deaths in the U.S. in 2015, which is about 1 of every 3 deaths.

Increasing prevalence of coronary heart disease, ischemic heart disease, and other cardiovascular diseases is expected to propel growth of the bioresorbable vascular scaffold market

Bioresorbable vascular scaffold is used in treatment of blockage of coronary and peripheral artery, which is related to coronary heart disease, ischemic heart disease, and other cardiovascular diseases. High prevalence of coronary heart disease, ischemic heart disease, and other cardiovascular diseases is expected to propel demand for bioresorbable vascular scaffold, which in turn will drive the market growth. According to World Health Organization (WHO), 2015, cardiovascular diseases is the first leading cause of morbidity and mortality worldwide, with around 17.7 million representing 31% of all global deaths in 2015, out of these deaths, an estimated 6.7 million were due to stroke and 7.4 million were due to coronary heart disease.

Similarly, according to American Heart Association in 2018, 92.1 million American adults were suffering with some form of cardiovascular disease or the after-effects of stroke. Nearly 836,546 deaths in the U.S. were due to cardiovascular disease, which is about 1 of every 3 deaths. Direct and indirect costs in the treatment of cardiovascular diseases and stroke were estimated to amount to US$ 329.7 billion in 2018, which includes both health expenditures and lost productivity, in the U.S.

Increasing adoption of bioresorbable vascular scaffolds in North America is expected to boost the market growth

North America is expected to be held dominant position in the global bioresorbable vascular scaffold market, owing to rapid growth in geriatric population, rising incidences of cardiac ailments, coronary & peripheral artery diseases, and increasing number of obese people in the region. According to World Population Prospects, the number of persons aged 80 or over is projected to triple by 2050, from 137 million in 2017, to 425 million in 2050 in the U.S., while this age bracket is expected to more than double globally, rising from 962 million in 2017 to 2.1 billion in 2050.

Moreover, key players in the market are focused on receiving regulatory approvals for novel products to reduce the burden of blood stream infections associated with bioresorbable vascular scaffolds. For instance, in May, 2018, Pursuit Vascular, Inc., received U.S. FDA clearance for broader indication of its ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients with bioresorbable vascular scaffolds.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2471

Key Players

Major players operating in the global bioresorbable vascular scaffold market include Abbott, Cook Medical, Boston Scientific Corporation, B. Braun Melsungen AG, Medtronic Plc., Stentys SA, MAQUET Holding B.V. & Co. KG (Getinge AB), W.L. Gore & Associates, C. R. Bard, Inc., and Theragenics Corporation.

[martynnx-blog]

Future of the U.S. Central Venous Catheter Market  Adds New Dimension to Innovations till 2026

Central venous catheters play a major role in modern healthcare. These catheters allow easy administration of intravenous fluids, blood products, medications, and parenteral nutrition, as well as offer hemodialysis access and hemodynamic monitoring. They are used in various diseases for longer duration therapies such as cancer (chemotherapy) and end stage renal disease (dialysis).

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2610

The U.S. central venous catheter market size was valued at US$ 825.9 million in 2018, and is expected to exhibit a CAGR of 6.2% over the forecast period (2018 – 2026).

Increasing prevalence of cancer is expected to propel growth of the central venous catheter market

Cancer is a class of chronic disease that is characterized by out-of-controlled growth of cells. According to The National Cancer Institute, 2013, there are over 100 different types of cancer that can be described from the type of cells they are formed from. According to the American Cancer Society, 2017, cancer is the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths.

According to the National Center for Chronic Disease Prevention and Health Promotion, 2017, around 30 million people or 15% of the U.S. adults were estimated to have chronic kidney.

According to the World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012. Furthermore, WHO stated that the number of new cases is expected to increase by around 70% by 2030. In 2015, cancer was responsible for 8.8 million deaths worldwide.

Market Dynamics

Increasing prevalence of renal diseases is a major factor driving the central venous catheter market growth. According to the National Center for Chronic Disease Prevention and Health Promotion, 2017, around 30 million people or 15% of the U.S. adults were estimated to have chronic kidney.

Moreover, introduction of innovative products and increasing requirement of long-duration IV therapies such as chemotherapy is expected to boost the market growth. For instance, in May, 2018, Pursuit Vascular, Inc., received the U.S. Food and Drug Administration (FDA) clearance for a broader indication of its ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients with central venous catheters (CVCs).

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2610

Key Players

Major players operating in the U.S. central venous catheter market include, AngioDynamics, Inc., C. R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc., Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc., ICU Medical, Inc., and Theragenics Corporation.

[martynnx-blog]

Blood Gas Analyzers Market Growth, Vendors, Industry Status, Applications, Developments, Regions

Blood gas analysis is performed for critically ill patient suffering from a respiratory or metabolic disorder. In blood gas analysis includes measurement of the amount of oxygen, carbon dioxide, and the acidity of pH in the blood as well as concentrations of other parameters such ascreatinine, electrolytes, glucose, hemoglobin, and lactate. Blood gas analyzers use electrodes to determine pH, partial pressure of carbon dioxide, and amount of oxygen in the blood. Imbalances in oxygen, carbon dioxide, and pH levels in blood can indicate the presence of certain medical conditions such as heart failure, hemorrhage, kidney failure, chemical poisoning, uncontrolled diabetes, or drug overdose.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2603

The global blood gas analyzers market size was valued at US$ 594.6 million in 2017 and is expected to witness a CAGR of 5.5% over the forecast period (2018 – 2026).

Increasing demand for point of care testing is expected to drive the blood gas analyzers market revenue

Blood gas analyzers are used for patients suffering from certain medical conditions, including asthma and Chronic Obstructive Pulmonary Disease (COPD). Emergency and intensive care departments also use blood gas analyzers as crucial part for assessment of patient’s clinical status.

Increasing geriatric population at high risk of various chronic diseases, which require frequent testing of blood gas and Point-of-Care (PoC) diagnostic evaluation is expected to drive growth of the global blood gas analyzer market. According to the U.S. Census Bureau, 2015, population of age 65 years and above is expected to increase over 60% during 2015 – 2030. Moreover, increasing number of patients being treated in ICUs and emergency departments is also expected to fuel the market growth. According to the WHO, in 2015, around three million deaths were caused by chronic diseases, which accounted for 5% of all the deaths worldwide. This in turn led to significant increase in emergency cases demanding for blood gas analyzers.

Market Dynamics

Increasing number of patients being treated in ICUs, NICUs, and emergency departments is propelling demand for blood gas analyzers. According to a NCBI report of 2017, in England, emergency services demand has increased by 125%, from around 4 million calls in 1994 and 1995 to 9 million ambulance calls in 2014 and 2015. Moreover, increasing number of patients suffering from chronic diseases such as cancer, cardiovascular disease, and lung disease also require blood gas testing. According to American Heart Association 2016 report, cardiovascular diseases are the leading cause of death worldwide, accounting for around 17.3 million deaths annually and is expected to reach over 23.6 million by 2030.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2603

Blood Gas Analyzers Market – Competitive Landscape

Key players operating in the global blood gas analyzers market include, Abbott Laboratories, Alere, Inc., Bayer AG, Dalko Diagnostics, GE Healthcare, Instrumentation Laboratory, Nova Biomedical, Radiometer, Roche Diagnostics, Siemens Healthcare, and Sphere Medical.

[martynnx-blog]

Beta Glucan Based Products Market Analysis, Trend, Future Scope, Demand, Leading Key Players and Industry Growth by Forecast to 2026

Beta glucan is a valuable dietary ?ber present in cereal crops, especially in barley, oat, and some mushrooms. According to the EC Nutrition journal: August 2017, beta glucans polysaccharide naturally found in the bran of cereal grains such as barley and oats and to a much lesser degree in rye and wheat, in amounts of around 7%, 5%, 2%, and less than 1%, respectively, the cell wall of baker’s yeast, certain types of fungi, and various types of mushrooms.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2597

Beta glucans promote health in a number of ways. Beta-glucans have been studied for their hypocholesterolemic effects. Furthermore, beta-1, 3-glucans improve the body’s immune system defense against foreign invaders by enhancing the ability of macrophages, neutrophils, and natural killer cells to respond to and fight bacteria, viruses, fungi, and parasites.

Moreover, growth of beta glucan based products market is attributed to increasing usage of beta-glucan as an immunity booster medicine in pharmaceutical and nutraceutical industry due to increasing demand for beta glucan in food & beverages and pharmaceuticals industry and increasing consciousness and concern about health & wellness among the global population.

The global beta glucan based products market size was valued at US$ 455.4 Mn in 2017 and is expected to witness a CAGR of 7.2% during the forecast period (2018 – 2026).

Changing consumer preferences towards the use of nutritious food supplements over synthetic ingredients is expected to drive the market growth during the forecast period Beta glucan is gaining interest among the population due to its multiple functional and bioactive properties. Beta glucan shows beneficial role in reducing insulin resistance, dyslipidemia, hypertension, and obesity. A study published in the Today’s Dietitian Journal: May 2014 stated that overweight men who consumed 7 g/day of beta-glucan for 12 weeks experienced a significant reduction in body mass, waist circumference, and visceral fat compared to those in the placebo group.

Subsequently, the application of β-glucan as a food ingredient is being widely considered with dual purposes of increasing the fiber content of food products and enhancing their health properties. As prevalence of cardiovascular disease (CVD) is increasing, identifying functional foods that reduce CVD risk factors (including high blood cholesterol) is an important area of research. Thus, oat β-glucan, a soluble dietary fiber found in the endosperm cell walls of oats,  has gained considerable interest due to its cholesterol-lowering properties.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2597

Key players operating in the beta glucan based products market include Jkosmmune, Lesaffre Group, Merck KGaA, Garuda International, Inc., Ohly GmBH, Koninklijke DSM N.V., Kerry Group PLC, STR Biotech Co. Ltd., Macrocare Tech Co., Ltd., Amarte USA, LLC, Ceapro Inc., Biotec Pharmacon ASA, Quegen Biotech Co., Ltd., Kemin Industries, Inc., NutraQ AS, Lantmännen, Carbon Medical Technologies, Inc., Givaudan SA, Danaher Corporation, Super Beta Glucan Inc. and AIPPO.

[martynnx-blog]

Immune Checkpoint Inhibitors Market Gain Impetus due to the Growing Demand over 2026

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2560

Introduction of novel immune checkpoint inhibitors with less side effects is driving global immune checkpoint inhibitors market growth

Cancer treatment has become more refined with improved treatment success rate due to improved therapeutic outcomes. This has been possible due to better understanding of the disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Immune checkpoint inhibitors exhibit lesser side effects as compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Manufactures are developing immune checkpoint inhibitors, which are tailored to attack or block particular targets. For instance, Iplimumab, a human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Moreover, in April 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC), who are not eligible for cisplatin chemotherapy, which is currently in the clinical phase 4.

The global immune checkpoint inhibitors market size was valued at US$ 10,543.8 million in 2017, and is expected to witness a robust CAGR of 11.8% over the forecast period (2018 – 2026).

Market Dynamics

Global Immune checkpoint inhibitors market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline of immune checkpoint inhibitor combination therapies. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immune checkpoint inhibitors combination therapies in the pipeline. Immune checkpoint inhibitors has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost global immune checkpoint inhibitors market growth over the forecast period.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2560

Some of the major players operating in the immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.

[martynnx-blog]

Veterinary Dentistry Instruments & Equipment Market Report Size, Industry Share, Worldwide Trends, In Depth Analysis of Historical, Growth Opportunities and Forecast to 2026

Veterinary dentistry includes adjustment, cleaning, extraction, filing, repair of animal teeth, and other aspects of animal oral healthcare. Dental diseases if left untreated can cause loss of teeth, oral infection, pain, and gingivitis. Advancements in instruments and devices used in veterinary dentistry has contributed to precision and atraumatic dental treatment.

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2554

Veterinary Dentistry Instruments & Equipment Market Drivers

Increasing number of veterinary specialists is expected to drive the global veterinary dentistry instruments & equipment market growth. For instance, according to American Veterinary Medical Foundation (AVMA), the number of active certified veterinary diplomates in the U. S. increased from 11,417 in December 2013 to 13,035 in December 2017. This increase is expected to lead to high demand for veterinary instruments and equipment and is expected to boost the global veterinary dentistry instruments & equipment market growth over the forecast period.

Leading manufacturers are focused in research and development of new devices, which is expected to have positive impact on the global veterinary dentistry instruments & equipment market growth. For instance, in February 2016 DRE Veterinary — an Avante Health Solutions company — announced the launch of new veterinary radiology unit —‘DRE Stationary DR X-ray System’. It is an X-ray machine, which delivers high-quality images with low dose of X-rays.

Furthermore, increasing prevalence of pet dental problems is expected to boost the global veterinary dentistry instruments & equipment market growth over the forecast period. For instance, according to AVMA, 70% of cats and 80% of dogs exhibit symptoms of dental care at the age of 3.

Veterinary Dentistry Instruments & Equipment Market Regional Analysis

In North America, key market players are focusing on organic and inorganic growth strategies to enhance their market share. For instance, in May 2015, Patterson Companies, Inc. — a Minnesota-based company that sells and distributes animal health products — announced acquisition of Animal Health International, Inc.— a Texas-based animal health products company.

Key manufactures are also focused in new product launch to expand their product offering. For instance, in June 2018, ACTEON North America, Inc. — a New Jersey-based electronic dental equipment company — announced the launch of Piezotom Cube — an ultrasonic bone surgery device, which makes tooth extractions atraumatic. Device uses high frequency ultrasonic vibrations, which selectively disrupt the bone without damaging the soft tissue. This excludes the requirement of cutting a surgical flap in the gingiva, thereby preserving the periosteum and most importantly reduces pain, trauma, and swelling experienced by patients post operations.

Such growth strategies are expected to boost the global veterinary dentistry instruments & equipment market growth over the forecast period.

Veterinary Dentistry Instruments & Equipment Market Restraints

Veterinary doctors in developed economies such as the U.S. follow American Animal Hospital Association (AAHA) dental care guidelines for treatment of pets. However, some emerging economies may lack such guidelines for veterinary treatment. Moreover, unlike developed economies, the practice of pet health insurance is also not exercised in most of the emerging countries. These factors are expected to restrain the global veterinary dentistry instruments & equipment market growth over the forecast period.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2554

Veterinary Dentistry Instruments & Equipment Market Key Players

Some of the key players operating in the global veterinary dentistry instruments & equipment market include, DRE Veterinary, Dispomed ltd., Dentalaire International, GerMedUSA, ACTEON North America, iM3 Dental Limited., Virbac, Serona Animal Health, Spectrum Medical X-Ray Co., and Henry Schein, Inc.

[martynnx-blog]

Spine Surgery Devices Market Technological Innovation Zimmer Biomet Holdings Inc., Stryker Corporation, DePuy Spine Inc

Spinal injuries can occur due to damage of vertebrae, ligaments, or discs of the vertebral column. The higher is the injury on the vertebral column, more effect of the injury is likely to occur as it is nearer to the brain. Such injuries can be treated by surgical procedures. However surgeries do not treat damages, but can reduce the deformity, relieve the pain and help in alignment of the spine (if fractured). The devices of the surgery that are required depend on the approach of the treatment chosen by the surgeon.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2645

Global Spine Surgery Devices Market Drivers

Frequent approvals by regulatory bodies of novel surgical devices used in spinal injury is expected to drive the global spine surgery devices market growth. For instance, in September 2018, Meditech Spine LLC received approval by the U.S. Food and Drug Administration (FDA) to market its product Cure Opel – C system. Cure Opel – C system is an additional technology to its already existing product Cure ACP system and Talos – C (HA) Interbody System. It provides a unique lock mechanism, which prevents backing out of screws once fixed in the vertebral column.

Furthermore, in January 2017, Camber Spine Technologies, LLP received an approval by the U.S. FDA for its product Siconus SI Fusion Screw System. It provides support and fixation to larger bones like sacrum. Camber Spine Technologies developed this system with the partnership of Institute for Musculoskeletal Science & Education. Such approvals of novel devices by regulatory bodies is expected to propel the global spine surgery devices market growth.

Global Spine Surgery Devices Market Restraints

Complications in surgical procedures related to spinal injuries may influence the adoption of these surgeries and thus, hampering the global spine surgery devices market growth. According to National Health Services (NHS), U.K., all surgeries are associated with some kind of risks. For instance, in lumbar decompression surgery (Laminectomy) there is a risk of infection at the location of invasion. It also includes risk of blood clots, accidental damage to the nerves, loss of vision, and facial sores. Hence, this factor is expected to hinder the global spine surgery devices market growth.

Global Spine Surgery Devices Market Key Players

Some of the major players operating in the global spine surgery devices market include Zimmer Biomet Holdings Inc., Stryker Corporation, DePuy Spine Inc., Medtronic plc, Globus Medical Inc., Smith and Nephew plc, Arthrex , Inc., Paradigm Spine LLC, Meditech Spine LLC, and Alphatech Spine Inc.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/spine-surgery-devices-market-2645

[martynnx-blog]

Pregnancy Testing Devices Market Booming Rapidly With Players Piramal Enterprises, Alere Inc., Prestige Brands Holdings Inc.

Pregnancy testing devices are medical devices that help in identifying the possibility of pregnancy. Pregnancy testing devices analyze the samples of women’s blood or urine for the presence of human chorionic gonadotrophin (HCG). The device detects tiny amount of HCG, a female pregnancy hormone that increases during early stages of pregnancy in female body. The urine pregnancy test kit provides qualitative results i.e. positive or negative. It contains the test strip, which is directly exposed to the potential women’s urine. The blood test kit is the most sensitive pregnancy test. The test allows the clinician to detect exact levels of HCG in women’s blood, which is based on HCG molecules bound on the test strip.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2635

Global Pregnancy Testing Device Market Drivers

Rise in demand for the fast, self-contained tests results, growing age of first pregnancy, continuous technological advancement, and attractive product features such as smartphone app connectivity in pregnancy test device are likely to drive growth of global pregnancy test device market over the forecast period. Moreover, growing awareness regarding the availability of pregnancy testing devices and utilization of self-detection pregnancy device, increased healthcare expenditure, rise in disposable income, and increase in prevalence of teenage pregnancy also stimulate the market growth. In April 2015, Abbott Laboratories received the U.S. FDA approval for its I-STAT TOTAL HCG test for rapid and accurate detection of HCG hormone in pregnant women.

Global Pregnancy Testing Device Market - Regional Insights

North America holds dominant position in the global pregnancy testing device market, owing to high healthcare expenditure and awareness programs taken by companies regarding the effective usage of pregnancy testing devices. For instance, in December 2017, Lia diagnostics, U.S., developed a flushable pregnancy test that is made from sustainable biodegradable materials. The company claims that this pregnancy kit will be available over the counter and is the world’s first and only flushable, biodegradable pregnancy test. Europe is expected to witness higher growth rate in the forecast period, owing to high adoption of digital pregnancy detecting device over the forecast period. Latin America is also an emerging market, owing to the increasing awareness regarding benefits of pregnancy detection in early stage and affordability of pregnancy detection kits.

Global Pregnancy Testing Device Market - Competitive Landscape

Some of the key players operating in the global pregnancy testing device market include Piramal Enterprises, Alere Inc., Prestige Brands Holdings Inc., Quidel Corporation., Procter and Gamble Co., Cardinal Health, and Confirm Biosciences.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/pregnancy-testing-devices-market-2635